The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.
R. Hassan
No relevant relationships to disclose
E. Sharon
No relevant relationships to disclose
B. Schuler
No relevant relationships to disclose
Y. Mallory
No relevant relationships to disclose
J. Zhang
No relevant relationships to disclose
A. Ling
No relevant relationships to disclose
I. Pastan
No relevant relationships to disclose